The team will present its device and research findings at the American Chemical Society’s fall meeting, according to an Aug. 19 news release from the organization.
The device is called an electrochemical capillary-driven immunoassay and screens for biomarker proteins previously correlated with heart failure, Galectin-3 and S100A7, from a drop of saliva.
In collaboration with Griffith University in Queensland, Australia, researchers are set to test the device in a human trial at the university, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
